Francisco‐Javier Peñalver

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · The Lancet Oncology · 2010 · 459 citations

Hematological Malignancy, Elderly Patients, Medicine +7

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · Blood · 2012 · 143 citations · Full text

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · Blood · 2014 · 102 citations · Full text

Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)

Francisco‐Javier Peñalver, Juan‐Manuel Sancho, Adolfo de la Fuente et al. · Haematologica · 2016 · 64 citations · Full text

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

María‐Victoria Mateos, Norma C. Gutiérrez, María-Luisa Martín-Ramos et al. · Blood · 2011 · 57 citations · Full text